Targeting therapeutic gene expression to human prostate cancers

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 4, 2000, Pages 389-399

  Maitland, N J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Gene targeting; Prostatic cancer; Specificity

Indexed keywords

BICALUTAMIDE; CELL SURFACE RECEPTOR; FLUTAMIDE; GONADORELIN ANTAGONIST; KALLIKREIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; VIRUS PROTEIN;

ARTICLE; CANCER SURVIVAL; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; ORCHIECTOMY; PROSTATE CANCER; PROSTATECTOMY;

ANIMALS; CELL MEMBRANE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0033844509     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (132)

1. Changing trends in prostatic cancer
2. Why is the prostate cancer death rate declining in the United States?
3. The European Randomized Study of Screening for Prostate Cancer (ERSBC): An update
4. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma
5. Histological grading of prostate cancer
6. Current and proposed biological markers in prostate cancer: 1994
7. What causes prostate cancer? A brief summary of the epidemiology
8. Family history and prostate cancer risk
9. Familial prostate cancer: The evidence and the Cancer Research Campaign British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study
10. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate-specific antigen: A prospective multicenter clinical trial
11. 3D Conformal radiation therapy (3DCRT) for high-grade prostate cancer: A multi-institutional review
12. Studies on prostate cancer II. The effects of castration on advanced carcinoma of the prostate gland
13. Prospects for the treatment of endocrine-responsive tumors
14. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
15. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials
16. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
17. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs
18. Targeted gene delivery to mammalian cells by filamentous bacteriophage
19. Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells
20. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
21. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
22. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways
23. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
24. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
25. Generating improved single-chain Fv molecules for tumor targeting
26. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration
27. Gonadotropin-releasing hormone analog conjugates with strong selective antitumor activity
28. Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog
29. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
30. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells
31. Caveolin-I expression in clinically confined human prostate cancer: A novel prognostic marker
32. High expression of a specific T-cell receptor γ transcript in epithelial cells of the prostate
33. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma
34. Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma
35. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer
36. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations
37. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation
38. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers
39. Insulin-like growth factor (IGF) network and prostate pathologies
40. Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines
41. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia
42. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor
43. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells
44. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance
45. 5E10: A prostate-specific surface-reactive monoclonal antibody
46. A novel monoclonal antibody 107-1A4 with high prostate specificity: Generation, characterization of antigen expression, and targeting of human prostate cancer xenografts
47. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas
48. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
49. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
50. STEAP: A prostate-specific cell surface antigen highly expressed in human prostate tumors
51. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family
52. Prostate-specific membrane antigen expression in normal and malignant human tissues
53. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases
54. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
55. Immunocytochemical localization of an Immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2'-deoxyuridine) in human prostate tumors
56. Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis
57. An expressed-sequence-tag database of the human prostate: Sequence analysis of 1168 cDNA clones
58. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray
59. PART-1: A novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12
60. Tissue-specific and androgen-regulated expression of human prostate-specific transglutaminase
61. The human prostate-specific transglutaminase gene (TGM4): Genomic organization, tissue-specific expression, and promoter characterization
62. Human prostate-specific transglutaminase: A new prostatic marker with a unique distribution pattern
63. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression
64. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression
65. Nucleotide sequence of human prostatic acid phosphatase ACPP gene, including seven Alu repeats
66. Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene
67. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
68. Transcription factors: Important tools and targets for molecular medicine
69. Isolation ad androgen regulation of the human homeobox cDNA, NKX3.1
70. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer
71. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice
72. Selective activation of the probasin androgen-responsive region by steroid hormones
73. Steroid 5α-reductase: Two genes/two enzymes
74. Expression and regulation of steroid 5α-reductase 2 in prostate disease
75. The localization and expression of 5α-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures
76. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
77. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans
78. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene
79. Cloning and characterization of the prostate-specific membrane antigen promoter
80. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
81. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer
82. Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer
83. Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression
84. The prostate expression database (PEDB): Status and enhancements in 2000
85. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer
86. Identification of the deoxyribonucleic acid-binding site of a regulatory protein involved in prostate-specific and androgen receptor-dependent gene expression
87. Evolutionary analysis of TATA-less proximal promoter function
88. Structural comparison of human and rat prostate-specific acid phosphatase genes and their promoters: Identification of putative androgen response elements
89. Distinct regulatory elements govern Fgf4 gene expression in the mouse blastocyst, myotomes, and developing limb
90. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells
91. The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?
92. Androgen regulation of gene expression
93. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model
94. Development of seven new human prostate tumor xenogreft models and their histopathological characterization
95. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar
96. Cell-cell interaction in prostate gene regulation and cytodifferentiation
97. Role of the bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention
98. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
99. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study
100. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer
101. Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression
102. Antisense c-myc retroviral vector suppresses established human prostate cancer
103. Transcription factor Sp1 activates involucrin promoter activity in non-epithelial cell types
104. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells
105. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation
106. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21(WAF1/CIP1) and p16(CDKN4)) in human prostate cancers
107. Regulation of Akt PKB activity, cellular growth and in prostate carcinoma cells by MMAC/PTEN
108. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas
109. Re-expression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition
110. Androgen receptor localization and turnover in human prostate epithelium treated with the anitandrogen, casodex
111. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo
112. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector
113. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
114. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine
115. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
116. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
117. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
118. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
119. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine
120. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice
121. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
122. Prostate attenuated replication competent adenovirus (ARCA) CN-706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
123. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G-207
124. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
125. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
126. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
127. Gene therapy for prostate cancer. New perspectives on an old problem
128. Gene therapy for prostate cancer
129. Urological applications of gene therapy
130. NIH under fire over gene therapy trials
131. NIH tightens up monitoring of gene therapy mishaps
132. Precise microdissection of human prostate cancers reveals genotypic heterogeneity